CanSino's polio vaccine candidate receives China clinical trial approval

CanSino Biologics announced that its Recombinant Trivalent Poliomyelitis Vaccine has obtained clinical trial approval from China's National Medical Products Administration, allowing the company to initiate clinical trials.

The vaccine uses protein structure design and virus-like particle assembly technology, eliminating the need for viral genetic material or live virus in production. It aligns with World Health Organization recommendations for non-infectious polio vaccines.